НПВП в лечении пациенток с первичной дисменореей

Читать PDF

Аннотация

Первичная дисменорея является одной из наиболее частых форм нарушения менструального цикла в молодом возрасте. Нередко она приводит к утрате трудоспособности пациенток на несколько дней и требует назначения эффективных и быстродействующих средств. Первой линией терапии при первичной дисменорее признаны нестероидные противовоспалительные препараты (НПВП). При стойком нарушении менструальной функции, приводящем к повторяющимся эпизодам боли, возможно назначение комбинированных гормональных контрацептивов. Эффективность альтернативных методов лечения хотя и подтверждена рядом исследователей, однако уступает традиционным подходам. Согласно последним данным высокую эффективность в лечении первичной дисменореи показал НПВП ибупрофен в дозе 400 мг.

Ключевые слова: первичная дисменорея, НПВП, ибупрофен 400 мг.

________________________________________________

Primary dysmenorrhea is one of the most common forms of menstrual disorders in young age. This often leads to disablement of patients for several days and requires high-speed and efficient preparations. The first line of therapy in primary dysmenorrhea is considered to be the nonsteroidal anti-inflammatory agents (NSAIDs). When persistent menstrual dysfunction occurs, leading to recurrent episodes of pain, perhaps the appointment of combined hormonal contraceptives can be considered as the best method. The effectiveness of alternative treatments, although confirmed by a number of researchers, it lags behind the traditional approaches. According to recent data, the highest efficiency in the treatment of primary dysmenorrhea was shown by NSAID ibuprofen 400 mg.

Key words: primary dysmenorrhea, NSAIDs, ibuprofen 400 mg.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Umland EM, Weinstein LC, Buchanan EM. Menstruation-related disorders. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill; 2011.
2. Lefebvre G, Pinsonneault O, Antao V et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005; 27: 1117–46.
3. Hall JE. Menstrual disorders and pelvic pain. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill, 2012.
4. Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health Care 1988; 9: 398–402.
5. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151: 905–13.
6. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68: 661–4.
7. Iglesias EA, Coupey SM. Menstrual cycle abnormalities. Diagnosis and management. Adolesc Med 1999; 10 (2): 255–73.
8. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999; 60 (2): 489–96.
9. Banikarim C, Middleman AB. Primary dysmenorrhea in adolescents. Up To Date Online.
10. Emans SJ, Laufer RL, Goldstein DP. Pediatric & adolescent gynecology. 5th ed. Philadelphia. Lippincott, Williams & Wilkins, 2005; p. 417–22.
11. Twigg J. Dysmenorrhoea. Curr Obstet Gynaecol 2002; 12: 341–5.
12. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87 (1): 55–8.
13. Pullon S, Reinken J, Sparrow M. Prevalence of dysmenorrhoea in Wellington women. N Z Med J 1988; 101 (839): 52–4.
14. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990; 97 (7): 588–94.
15. Harlow S, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 1996; 103 (11): 1134–42.
16. Kritz-Silverstein D, Wingard DL, Garland FC. The association of behavior and lifestyle factors with menstrual symptoms. J Womens Health Gend Based Med 1999; 8 (9): 1185–93.
17. Alonso C, Coe CL. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol 2001; 20 (6): 411–6.
18. Purcell KJ, Taylor RN. Disorders of the female reproductive tract. Pathophysiology of Disease: An Introduction to Clinical Medicine. 6th ed. New York, NY: McGraw-Hill, 2010.
19. Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 2012; 119: 1143–50.
20. Zhu X, Proctor M, Bensoussan A et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2008; 2: CD005288.
21. Патофизиология. Учебник. В 2 т. Под ред. В.В.Новицкго, Е.Д.Гольдберг, О.И.Уразовой. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2012.
22. Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev 2010; 2: CD004142.
23. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; 1: CD001751.
24. SOGC clinical practice guideline. JOGC Décembre 2005; 169: 1117–30.
25. Barbieri RL. Primary dysmenorrhea in adults. Up To Date Online.
26. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105: 780–9.
27. De Mello NR, Baracat EC, Tomaz G et al. Double-blind study to evaluate efficacy and safety of meloxicam 7,5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 2004; 83: 667–73.
28. Henry D et al. BMJ 1996; 312: 1563–6.
29. Castellasgue J et al. Drug Safety 2012; 35: 1127–46.
30. Debski R. Comparative efficacy and tolerability of drotaverine 80 mg and ibuprofen 400 mg in patients with primary dysmenorrhoea – protocol DOROTA. Ginekol Pol 2007; 78 (12): 933–8.
31. Hauksson A, Ekström P, Juchnicka E et al. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989; 68 (1): 31–4.
32. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; 4: CD002120.
33. Dawood MY. Primary Dysmenorrhea. Advances in Pathogenesis and Management. Obstet Gynecol 2006; 108: 428–41.
34. Клиническая фармакология нестероидных противовоспалительных средств. Под ред. Ю.Д.Игнатова, В.Г.Кукеса, В.И.Мазурова. М.: ГЭОТАР-Медиа, 2010.
35. Marchini M et al. International J Clin Pharm Therap 1995; 9: 491–7.
36. Colombo F et al. Comparative evaluation of the efficacy of naproxen sodium and ibuprofen in the treatment of primarydysmenorrhea. Ann Ost Ginecol Med Perinat 1990; 111 (3): 205–8.
37. Инструкция по медицинскому применению препарата Нурофен Экспресс Леди.
38. American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG), 2010.

________________________________________________

Авторы

В.В.Коренная

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва

________________________________________________

V.V.Korennaya

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.